Targets › TH
1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Oct 2028.
Catalyzes the conversion of L-tyrosine to L-dihydroxyphenylalanine (L-Dopa), the rate-limiting step in the biosynthesis of catecholamines, dopamine, noradrenaline, and adrenaline. Uses tetrahydrobiopterin and molecular oxygen to convert tyrosine to L-Dopa. (UniProt, P07101)
Open in Phaseline: the race on TH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BlueRock Therapeutics | bemdaneprocel Midbrain dopaminergic neuron progenitors derived from human embryonic stem cells | TH | Phase 3 | Parkinsons Disease (PD) | Oct 2028 |
Parkinsons Disease (PD) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.